Drug intelligence / Profile preview

AT-04

Development stage: Preclinical
Lead developer: Attralus
Modality: Peptides

Overview

AT-04 is a therapeutic candidate developed by Attralus, a clinical-stage biopharmaceutical company. It is a peptibody designed as a pan-amyloid removal (PAR) therapeutic for neurodegenerative diseases. Attralus has partnered with Ossianix to combine AT-04 with Ossianix's TXP1 brain shuttle technology to enhance its brain penetration.

Targets

Amyloid fibrilsFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on AT-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-04.

Explore the full profile